AN2 Therapeutics Statistics Share Statistics AN2 Therapeutics has 27.33M
shares outstanding. The number of shares has increased by 1.12%
in one year.
Shares Outstanding 27.33M Shares Change (YoY) 1.12% Shares Change (QoQ) 0.26% Owned by Institutions (%) 43.35% Shares Floating 17.74M Failed to Deliver (FTD) Shares 310 FTD / Avg. Volume 0.32%
Short Selling Information The latest short interest is 30.46K, so 0.11% of the outstanding
shares have been sold short.
Short Interest 30.46K Short % of Shares Out 0.11% Short % of Float 0.19% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.8 and the forward
PE ratio is -1.34.
AN2 Therapeutics's PEG ratio is
0.02.
PE Ratio -0.8 Forward PE -1.34 PS Ratio 0 Forward PS 0.5 PB Ratio 0.5 P/FCF Ratio -0.84 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for AN2 Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.43,
with a Debt / Equity ratio of 0.
Current Ratio 8.43 Quick Ratio 8.43 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.33M Employee Count 22 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 20.95% in the
last 52 weeks. The beta is -0.07, so AN2 Therapeutics's
price volatility has been lower than the market average.
Beta -0.07 52-Week Price Change 20.95% 50-Day Moving Average 1.15 200-Day Moving Average 1.21 Relative Strength Index (RSI) 56.24 Average Volume (20 Days) 96,512
Income Statement
Revenue n/a Gross Profit n/a Operating Income -54.55M Net Income -51.32M EBITDA -51.32M EBIT -51.32M Earnings Per Share (EPS) -1.72
Full Income Statement Balance Sheet The company has 21.35M in cash and 0 in
debt, giving a net cash position of 21.35M.
Cash & Cash Equivalents 21.35M Total Debt n/a Net Cash n/a Retained Earnings -205.78M Total Assets 75.83M Working Capital 65.41M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -49.26M
and capital expenditures 0, giving a free cash flow of -49.26M.
Operating Cash Flow -49.26M Capital Expenditures n/a Free Cash Flow -49.26M FCF Per Share -1.65
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
